About Synthego
Synthego is a genome engineering company that enables access to CRISPR to accelerate life science research and development.
Headquarters
Synthego, Redwood City
Founded
2012-07-01
Industry
Artificial Intelligence (AI), Biotechnology, Genetics, Industrial Automation, Innovation Management, Life Science, Machine Learning, Software
Last Funding Type
Series E
Valuation
1
Total Funding
$459.69 million dollars
IPO Status
Private
Financial
Synthego is advancing genome engineering through CRISPR technology. They focus on guide RNA sequencing confirmation and design, as well as methods for analyzing nucleic acid sequences. Their research includes systems for modulating CRISPR activity and conjugated CRISPR-Cas complexes. Additionally, they develop methods for cryogenically arrayable stable transfection and systems for processing cells, including automated oligonucleotide synthesis. These efforts highlight Synthego's commitment to enhancing CRISPR-based gene editing and cell processing technologies.
Synthego's CEO will step down to focus the company on CRISPR therapeutics. Concurrently, Synthego spins off EditCo Bio, transferring its engineered cell solutions to the new entity. This strategic move aims to enhance focus on therapeutic applications of CRISPR technology.
Synthego's CEO will step down to focus the company on CRISPR therapeutics. Concurrently, Synthego spins off EditCo Bio, transferring its engineered cell solutions to the new entity. This strategic move aims to enhance focus on therapeutic applications of CRISPR technology.
Funding Rounds
9
Number of Lead Investors
5
Total Funding Amount
$459.69 million dollars
Number of Investors
29